As­traZeneca’s Imfinzi/treme­li­mum­ab com­bo fiz­zles again on lung can­cer

As­traZeneca has found an­oth­er trap door for its com­bi­na­tion of the PD-L1 check­point Imfinzi and its CT­LA-4 com­bi­na­tion drug treme­li­mum­ab.

The re­search team on ARC­TIC says the com­bo has failed on both pro­gres­sion-free sur­vival as well as over­all sur­vival, un­able to beat chemo stan­dard of care as a third-line ther­a­py for non-small cell lung can­cer.

The phar­ma gi­ant says it did de­tect a clin­i­cal­ly mean­ing­ful ef­fect for Imfinzi alone in this group, but didn’t pow­er the study to demon­strate sta­tis­ti­cal sig­nif­i­cance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER